secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anteris Technologies Global Corp. (AVR)
CIK:        0002011514
Form:       8-K
Filed at:   2026-08-11T23:07:30+00:00
Accession:  0001140361-26-032296
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anteris six-month 2026: revenue $1.503M (+28% YoY), net loss widens to $52.1M
-----------------------------------------------------------------------------

- Six-month revenue $1.503M vs $1.174M prior year; loss attributable to members $52.118M vs $42.698M (22% worse).
- Q2 2026 net operating cash outflows $20.8M; R&D expenses $23.4M driven by PARADIGM trial scaling and manufacturing.
- CMS granted Medicare reimbursement for PARADIGM trial procedures under TAVR NCD 20.32; U.S. enrollment began May 2026.
- Trial active in U.S., Denmark, Netherlands; regulatory clearance secured in Canada and France; ~1,000-patient randomized study.
- No dividend proposed; board appointments of Susan Knight and Stephen Denaro during the quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2011514/000114036126032296/0001140361-26-032296-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2011514/000114036126032296/ef20079835_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-032296

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer